Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer

References

• Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 cancer incidence, mortality and prevalence worldwide. IARC Cancerbase no. 5, version 2.0, IARC Press, Lyon, France (2004).
   Google Scholar
• Parkin DM, Whelan SL, Ferlay J. Cancer Incidence in Five Continents Volume VII. International Agency for Research on Cancer, Lyon, France, 822–823 (1997).
   Google Scholar
• Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern. Med.47(12), 1077–1083 (2008).
   PubMed Web of Science ®Google Scholar
• Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet374(9688), 477–490 (2009).
   PubMed Web of Science ®Google Scholar
• Correa P, Chen VW. Gastric cancer. Cancer Surv.19–20, 55–76 (1994).
   PubMedGoogle Scholar
• Aragonés N, Pollán M, Rodero I, López-Abente G. Gastric cancer in the European Union (1968–1992): mortality trends and cohort effect. Ann. Epidemiol.7(4), 294–303 (1997).
   PubMed Web of Science ®Google Scholar
• Stewart BW, Kleihues P. World Health Organization International Agency for Research on Cancer. World Cancer Report (2003).
   Google Scholar
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol.24(14), 2137–2150 (2006).
   PubMed Web of Science ®Google Scholar
• Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit. Rev. Oncol. Hematol.71(2), 127–164 (2009).
   PubMed Web of Science ®Google Scholar
• Hartgrink HH, van de Velde CJ, Putter H et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J. Clin. Oncol.22, 2069–2077 (2004).
   PubMed Web of Science ®Google Scholar
• Ajani JA, Fodor MB, Tjulandin SA et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J. Clin. Oncol.23, 5660–5667 (2005).
   PubMed Web of Science ®Google Scholar
• Barone C, Corsi DC, Pozzo C et al. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin based regimen: two parallel randomized Phase II studies. Cancer82, 1460–1467 (1998).
   PubMed Web of Science ®Google Scholar
• Bouche’ O, Raoul JL, Bonnetain F et al. Randomized multicenter Phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study – FFCD 9803. J. Clin. Oncol.22, 4319–4328 (2004).
   PubMedGoogle Scholar
• Hong YS, Song SY, Lee SI et al. A Phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann. Oncol.15, 1344–1347 (2004).
   PubMed Web of Science ®Google Scholar
• Kohne CH, Catane R, Klein B et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a Phase II multicentric trial. Br. J. Cancer89, 997–1001 (2003).
   PubMed Web of Science ®Google Scholar
• Koizumi W, Saigenji K, Ujiie S, Terashima M, Sakata Y, Taguchi T. A pilot Phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology64, 232–236 (2003).
   PubMed Web of Science ®Google Scholar
• Moehler M, Eimermacher A, Siebler J et al. Randomised Phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br. J. Cancer92, 2122–2128 (2005).
   PubMed Web of Science ®Google Scholar
• Nardi M, Azzarello D, Maisano R et al. FOLFOX-4 regimen as firstline chemotherapy in elderly patients with advanced gastric cancer: a safety study. J. Chemother.19, 85–89 (2007).
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J. Clin. Oncol.24, 2188–2196 (2006).
   PubMed Web of Science ®Google Scholar
• Pozzo C, Barone C, Szanto J et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal–gastric junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol.15, 1773–1781 (2004).
   PubMed Web of Science ®Google Scholar
• Chua YJ, Cunningham D. The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann. Surg. Oncol.14(10), 2687–2690 (2007).
   PubMed Web of Science ®Google Scholar
• Koizumi W. Available options in chemotherapy for advanced gastric cancer: the current developments in Japan. Expert Opin. Pharmacother.6(2), 225–231 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S et al.; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J. Clin. Oncol.24(31), 4991–4997 (2006).
   PubMed Web of Science ®Google Scholar
• Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J. Gastroenterol.43(4), 256–264 (2008).
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med.352, 2696–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br. J. Cancer90, 1190–1197 (2004).
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Duyster J, Lersch C et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a Phase II trial. Br. J. Cancer92, 2129–2133 (2005).
   PubMedGoogle Scholar
• Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer34, 1274–1281 (1998).
   PubMed Web of Science ®Google Scholar
• Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother. Pharmacol.45, 291–297 (2000).
   PubMed Web of Science ®Google Scholar
• Comella P, Franco L, Casaretti R, de Portu S, Menditto E. Emerging role of capecitabine in gastric cancer. Pharmacotherapy29(3), 318–330 (2009).
   PubMedGoogle Scholar
• Sakamoto J, Chin K, Kondo K et al.; Clinical Study Group of Capecitabine. Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs17(2), 231–236 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JL, Kang YK, Kang HJ et al. A randomised multicentre Phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br. J. Cancer99(4), 584–590 (2008).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S et al.; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med.358(1), 36–46 (2008).
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol.20(4), 666–673 (2009).
   PubMed Web of Science ®Google Scholar
• Kim TW, Kang YK, Ahn JH et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann. Oncol.13, 1893–1898 (2002).
   PubMed Web of Science ®Google Scholar
• Kang HJ, Chang HM, Kim TW et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br. J. Cancer92(2), 246–251 (2005).
   PubMed Web of Science ®Google Scholar
• Lee SS, Lee JL, Ryu MH et al. Combination chemotherapy with capecitabine (X) and cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn. J. Clin. Oncol.37(1), 30–37 (2007).
   PubMedGoogle Scholar
• Kang HJ, Chang HM, Kim TW et al. A Phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br. J. Cancer98(2), 316–322 (2008).
   PubMed Web of Science ®Google Scholar
• Park YH, Ryoo BY, Choi SJ, Kim HT. A Phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br. J. Cancer90(7), 1329–1333 (2004).
   PubMed Web of Science ®Google Scholar
• Giordano KF, Jatoi A, Stella PJ et al.; North Central Cancer Treatment Group. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a Phase II study from the North Central Cancer Treatment Group. Ann. Oncol.17(4), 652–656 (2006).
   PubMed Web of Science ®Google Scholar
• Orditura M, Martinelli E, Galizia G et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a Phase II study. Ann. Oncol.17(10), 1529–1532 (2006).
   PubMedGoogle Scholar
• Thuss-Patience PC, Kretzschmar A, Dogan Y et al. Docetaxel and capecitabine for advanced gastric cancer: Phase II study investigating dose dependent efficacy in two patient cohorts. Presented at: 44th American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA, 30 May–3 June 2008.
   Google Scholar
• Park YH, Kim BS, Ryoo BY, Yang SH. A Phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br. J. Cancer94(7), 959–963 (2006).
   PubMed Web of Science ®Google Scholar
• van Meerten E, Eskens FA, van Gameren EC, Doorn L, van der Gaast A. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a Phase II study. Br. J. Cancer96(9), 1348–1352 (2007).
   PubMed Web of Science ®Google Scholar
• Jatoi A, Murphy BR, Foster NR et al.; North Central Cancer Treatment Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a Phase II study from the North Central Cancer Treatment Group. Ann. Oncol.17(1), 29–34 (2006).
   PubMed Web of Science ®Google Scholar
• Kim TW, Innocenti F. Insights, challenges, and future directions in irinogenetics. Ther. Drug Monit.29(3), 265–270 (2007).
   PubMed Web of Science ®Google Scholar
• Farhat FS. A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer. Med. Oncol.24(2), 137–146 (2007).
   PubMedGoogle Scholar
• Futatsuki K, Wakui A, Nakao I et al. Late Phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan. To. Kagaku. Ryoho.21(7), 1033–1038 (1994).
   PubMedGoogle Scholar
• Köhne CH, Catane R, Klein B et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a Phase II multicentric trial. Br. J. Cancer89(6), 997–1001 (2003).
   PubMed Web of Science ®Google Scholar
• Blanke CD, Haller DG, Benson AB et al. A Phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. Ann. Oncol.12(11), 1575–1580 (2001).
   PubMed Web of Science ®Google Scholar
• Pozzo C, Barone C, Szanto J et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized Phase II study. Ann. Oncol.15(12), 1773–1781 (2004).
   PubMed Web of Science ®Google Scholar
• Bouché O, Raoul JL, Bonnetain F et al.; Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study – FFCD 9803. J. Clin. Oncol.22(21), 4319–4328 (2004).
   PubMed Web of Science ®Google Scholar
• Dank M, Zaluski J, Barone C et al. Randomized Phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann. Oncol.19(8), 1450–1457 (2008).
   PubMed Web of Science ®Google Scholar
• Baek JH, Kim JG, Jeon SB et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br. J. Cancer94(10), 1407–1411 (2006).
   PubMed Web of Science ®Google Scholar
• Burge ME, Smith D, Topham C et al. A Phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. Br. J. Cancer94(9), 1281–1286 (2006).
   PubMed Web of Science ®Google Scholar
• Oh SC, Sur HY, Sung HJ et al. A Phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. Br. J. Cancer96(10), 1514–1519 (2007).
   PubMed Web of Science ®Google Scholar
• Leary A, Assersohn L, Cunningham D et al. A Phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother. Pharmacol.64(3), 455–462 (2009).
   PubMed Web of Science ®Google Scholar
• Farhat FS, Kattan J, Chahine GY et al. Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer. Med. Oncol. (2009) (In press).
   PubMedGoogle Scholar
• Moehler M, Kanzler S, Geissler M et al.; for the Arbeitsgemeinschaft Internistische Onkologie, Germany. A randomized multicenter Phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann. Oncol.21(1), 71–77 (2010).
   PubMed Web of Science ®Google Scholar
• Arnold D, Peinert S, Voigt W, Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist11(6), 602–611 (2006).
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmén M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol.16(2), 273–278 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol.27(Suppl. 20), 155 (2009) (Abstract LBA4509).
   PubMedGoogle Scholar
• Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. (2009) 71(1), 14–17 (2010).
   Google Scholar
• Liakakos T, Roukos DH. More controversy than ever – challenges and promises towards personalized treatment of gastric cancer. Ann. Surg. Oncol.15, 956–960 (2008).
   PubMedGoogle Scholar
• Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn.9(3), 217–221 (2009).
   PubMed Web of Science ®Google Scholar